Business Standard

Bharat Biotech's Covaxin is safe for children between 2 and 18 yrs: Lancet

Data from over 50 million doses reveals minimal side effects

Bharat Biotech has also finished administering the vaccines for its paediatric trial of Covaxin. Now, it is analysing the data before it can submit it to the regulator for review.
Premium

Bharat Biotech conducted phase 2/3, open-label and multicenter study to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 age group.

Sohini Das Mumbai
Bharat Biotech's Covaxin has proved to be safe, well-tolerated and immunogenic in the paediatric population in Phase-II and -III studies, according to a study published in the peer-reviewed journal The Lancet.

Bharat Biotech has a stockpile of more than 50 million doses of Covaxin ready to be distributed as required.

The company claimed that Covaxin is one of the first Covid-19 vaccines in the world to generate data in the 2-18 year age group. Data from over 50 million doses given to children in India reveals minimal side effects. This data is now peer-reviewed and published in The Lancet Infectious

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 17 2022 | 9:51 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com